NeuroPace reports record Q3 revenue $27.4M (+30% YoY); raises FY2025 guidance

NeuroPace Inc

2025-Q3 EPS reported -$0.58 vs consensus -$0.20 ▼ miss (-189.7%)

Record quarterly revenue of $27.4M, up 30% YoY; RNS System revenue $22.6M (+31% YoY).
Gross margin expanded to 77.4% from 73.2% YoY; operating loss narrowed to $2.6M from $4.2M.
Net loss improved to $3.5M from $5.5M YoY; cash and short-term investments $60M.
Raised FY2025 revenue guidance to $97M-$98M (21-23% YoY growth) and gross margin to 76%-77%.
On track to submit NAUTILUS PMA supplement to FDA for IGE indication expansion by year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.